GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
FiercePharma6h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
GSK lifts long-term sales targets on new drug pipeline
Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.
stockhead12h
Biocurious: Consumer health minnow Wellnex Life gears up for company-making Eurotrip
Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for European expansion.
Investment banks warn: Trump tariffs could derail Europe's 2025 growth
Trump's tariffs could derail Europe's 2025 growth, say top Wall Street analysts. Goldman Sachs sees eurozone GDP at 0.7%, ...